LNAI Overview

Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.

Wall Street analysts forecast LNAI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LNAI is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Lunai Bioworks Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Lunai Bioworks Inc. EPS for the last quarter amounts to 0.13 USD, decreased -104.61 % YoY.

Lunai Bioworks Inc (LNAI) has 29 emplpoyees as of January 26 2026.

Today LNAI has the market capitalization of 21.00M USD.